Dr. Daniel S. Welling, MD

Dr. Welling practices at Physicians for Women's Health in Rocky Hill, Connecticut.

Dr. Welling's NPI, 1427152644, was assigned on September 8, 2006. Dr. Welling holds Connecticut license 026697.

Dr. Welling's primary practice is Physicians for Women's Health, at 175 Capital Blvd, Rocky Hill, CT 06067 in Capitol County. The practice phone is (860) 678-3400.

Dr. Welling's primary practice is Physicians for Women's Health in Rocky Hill, Connecticut. The medical group on file is Physicians for Women. Dmand AI also links Dr. Welling to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Welling practices. Vendor and product names are available with a free account.

Obstetrics and gynecology is Dr. Welling's primary specialty in the NPI Registry, under taxonomy code 207V00000X. Dr. Welling is licensed in Connecticut.

CMS data shows 15 Medicare services from Dr. Welling across 1 procedure code in 2024, for 32 Medicare patients. Medicare paid $42 for them. Every service was in an office.

CMS counts 32 Medicare patients who saw Dr. Welling in 2024. The largest group is 65 to 74, with 15 patients. 72% of them have high cholesterol, and 59% have high blood pressure. Their average risk score is 1.33, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Welling's median patient age at 44, with 99% women.

In 2024, Dr. Welling wrote 209 Medicare Part D claims for 73 patients. 86% of them were for generic drugs. CMS names the drug for 100 of them, across 5 drugs with 11 or more claims each, at $3,652 in total drug cost. In 2023, CMS named 142 claims across 8 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Welling for performance year 2024, reported as part of a group. Dr. Welling accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 66 general payments to Dr. Welling from 30 drug and device companies from 2016 to 2024. Food and beverage make up the largest share, 96% of the total. Abbvie Inc. paid the most, $128.